MIMS reports on excepts from a recent dialogue on ‘The Leading Edge of Health Coaching: Empowering Patients in the Myriad of Daily Health Decisions’ at the recent Malaysian Innovative Healthcare Symposium (MIHS) 2019.
Nasopharyngeal cancer (NPC) is a disease in which cancer cells develop from the tissues of the nasopharynx – an area located behind the nose, just above the back of the throat. Chinese from endemic regions such as Hong Kong and Southern China have the highest risk of getting NPC. NPC is the ninth most common cancer among men in Singapore with the highest incidence in Chinese followed by Malays and is rare among Indians. [Singapore Cancer Registry Annual Registry Report, Trends in Cancer Incidence in Singapore 2015]
On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 20190807035449
Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.
Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1cof 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
Individuals with hearing disabilities often have issues with healthcare access due to communication gaps between them and medical staff. At the recent Beyond Dispensing: Malaysian Medical Sign Language 2019 workshop jointly organized by the Malaysian Community Pharmacy Business Forum (MyCPBF), the Malaysian Sign Language and Deaf Studies Association (MyBIM), The Light and the Malaysian Federation for the Deaf (MFD), a group of healthcare professionals took some time off to learn how to bridge the gaps.
At the recent 2nd Bayer Pharmacist Congress in July, a forum was held to discuss the topic of "Advancing the Role of Pharmacists in Primary Care". MPS and MCPG leaders shared their opinions on future directions of the profession and steps to take towards them.
Dr Andrew Ong, a consultant at the Department of Gastroenterology & Hepatology, Singapore General Hospital, explains to Roshini Claire Anthony the challenges in diagnosing and treating irritable bowel syndrome (IBS).
Assoc Prof Philip Eng, senior consultant respiratory physician at Mt Elizabeth Hospital in Singapore, shares his insights with Pearl Toh on diagnosing and managing pneumonia in the primary care setting.
In mid-March 2019, news of the Sungai Kim Kim chemical pollution disaster and its impact on thousands of Johor residents caught national attention. As healthcare services rushed in to provide medical aid, a temporary command centre was set up at Pasir Gudang Indoor Stadium to centralize efforts. MIMS Pharmacist spoke to three pharmacists about their experiences as volunteers there.
Daily use of the selective oral Bruton’s tyrosine kinase inhibitor evobrutinib in the treatment of patients with relapsing multiple sclerosis helps reduce the number of gadolinium-enhancing lesions, according to the results of a phase II trial.
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.